AB0186 Changes in bone turnover markers and vitamin d receptor (vdr) genotype during glucocorticoid therapy. (1st June 2001)

• Record Type: Journal Article
• Authors: Gantes, M; Arteaga, A; Barrios, Y; Ferraz, I; Alvarez, A; Rodríguez-Lozano, B; Batista, D; Trujillo, E; González, T
• Is Part Of: Annals of the rheumatic diseases. Volume 60(2001)Supplement 1
• Page Start: A246
• Page End: A246
• Publication Date: 2001-06-01
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2001.625
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Adverse effects of glucocorticoids (GCT) upon the skeleton and markers of bone turnover have been documented but the mechanisms remain unclear. Objectives: To test of early changes in markers of bone turnover for three months of GCT and the influence of VDR. Methods: In fifty three patients (age 41, 7 SD 12, 6) with inflammatory diseases who received a dose greater than 5 mg of prednisone or equivalent (mean dose 1, 9 g) for 3 months, the serum levels of parathyroid hormone (PTHi), 25-dihydroxyvitamin D, (Vit D), osteocalcin, alkaline phosphatase, and urine ratios of calcium/creatinine and deoxypyridinoline/creatinine, were determined baseline and 3 months after GCT. VDR genotypes were determined by PCR to demonstrate the presence (b) or absence (B) of a restriction target for Bsm I, in intron 7. Results: The patients with high baseline levels of PTHi showing lower levels of baseline VitD, (p = 0, 003) and 3 months after of GCT the patients with lower levels of PTH have the higher levels of Vit D, (p = 0, 001, r = 0, 54). There were no significant differences in biochemical markers of bone remodelling between the three genotypes: bb, BB, and Bb VDR before and 3 months after GCT. Conclusion: These preliminary results suggest not effect of VDR genotype in the changes of the biochemical markers of bone remodelling for glucocorticoid therapy.